NCT05646394View on ClinicalTrials.gov

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Antiphospholipid SyndromeArterial Thrombosis
Interventions
DRUG

Dual antiplatelet therapy

Aspirin plus any of clopidogrel, ticagrelor or prasugrel

DRUG

Combined antithrombotic therapy

Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.

DRUG

Vitamin K antagonist standard intensity

vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0

DRUG

Vitamin K antagonist high intensity

vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0

Trial Locations (3)

C1113 AAJ

RECRUITING

Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires, Buenos Aires

Unknown

RECRUITING

Clinica Universitaria Reina Fabiola, Córdoba

L9H 7M1

RECRUITING

McMaster University, Hamilton

All Listed Sponsors
collaborator

International Society on Thrombosis and Haemostasis

UNKNOWN

lead

McMaster University

OTHER